Magic mushroom compound may quiet the depressed Brain's endless Self-Criticism

NCT ID NCT06247839

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study investigates whether a single dose of psilocybin, the active compound in magic mushrooms, can reduce rumination—repetitive negative self-focused thinking—in people with major depressive disorder. Researchers will use brain scans to see how psilocybin changes activity in brain networks linked to self-related processing. The trial enrolls 20 adults with moderate to severe depression and measures changes in rumination, depression severity, and brain connectivity over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a single dose of psilocybin (COMP360)
What this could lead to
If it works, this could point toward a new way to treat depression by targeting rumination and self-focused thinking.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply broadly. Psilocybin can cause intense psychological effects and is not yet approved for depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Athinoula A. Martinos Center for Biomedical Imaging

    RECRUITING

    Charlestown, Massachusetts, 02129, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.